JP5985392B2 - 放射性免疫複合体を生成するための方法 - Google Patents

放射性免疫複合体を生成するための方法 Download PDF

Info

Publication number
JP5985392B2
JP5985392B2 JP2012521780A JP2012521780A JP5985392B2 JP 5985392 B2 JP5985392 B2 JP 5985392B2 JP 2012521780 A JP2012521780 A JP 2012521780A JP 2012521780 A JP2012521780 A JP 2012521780A JP 5985392 B2 JP5985392 B2 JP 5985392B2
Authority
JP
Japan
Prior art keywords
reaction mixture
acid
hum195
antibody
dota
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012521780A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013500258A (ja
Inventor
ジェイム サイモン
ジェイム サイモン
エイ ゲイロード キング
エイ ゲイロード キング
ベルムデス ホスエ マニュエル モレノ
ベルムデス ホスエ マニュエル モレノ
Original Assignee
アクティニウム ファーマシューティカルズ インコーポレイテッド
アクティニウム ファーマシューティカルズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アクティニウム ファーマシューティカルズ インコーポレイテッド, アクティニウム ファーマシューティカルズ インコーポレイテッド filed Critical アクティニウム ファーマシューティカルズ インコーポレイテッド
Publication of JP2013500258A publication Critical patent/JP2013500258A/ja
Application granted granted Critical
Publication of JP5985392B2 publication Critical patent/JP5985392B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2012521780A 2009-07-22 2010-07-22 放射性免疫複合体を生成するための方法 Active JP5985392B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22771009P 2009-07-22 2009-07-22
US61/227,710 2009-07-22
PCT/US2010/042885 WO2011011592A1 (en) 2009-07-22 2010-07-22 Methods for generating radioimmunoconjugates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016152696A Division JP2016199583A (ja) 2009-07-22 2016-08-03 放射性免疫複合体を生成するための方法

Publications (2)

Publication Number Publication Date
JP2013500258A JP2013500258A (ja) 2013-01-07
JP5985392B2 true JP5985392B2 (ja) 2016-09-06

Family

ID=43499411

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012521780A Active JP5985392B2 (ja) 2009-07-22 2010-07-22 放射性免疫複合体を生成するための方法
JP2016152696A Pending JP2016199583A (ja) 2009-07-22 2016-08-03 放射性免疫複合体を生成するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016152696A Pending JP2016199583A (ja) 2009-07-22 2016-08-03 放射性免疫複合体を生成するための方法

Country Status (8)

Country Link
US (1) US9603954B2 (https=)
EP (1) EP2456472B1 (https=)
JP (2) JP5985392B2 (https=)
CN (2) CN104710504B (https=)
CA (1) CA2768658C (https=)
IN (1) IN2012DN00551A (https=)
RU (2) RU2704802C2 (https=)
WO (1) WO2011011592A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12344675B2 (en) 2022-08-22 2025-07-01 Abdera Therapeutics Inc. Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex
US12600794B2 (en) 2024-07-23 2026-04-14 Abdera Therapeutics Inc. 5T4 binding polypeptides and uses thereof

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201208309D0 (en) * 2012-05-11 2012-06-27 Algeta As Complexes
US20150157742A1 (en) * 2013-12-11 2015-06-11 The European Atomic Energy Community (Euratom), Represented By The European Commission SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
CA2949365A1 (en) * 2014-05-16 2015-11-19 Memorial Sloan Kettering Cancer Center One-step labeling of antibodies to high specific activity with actinium-225
CN108348604B (zh) * 2015-09-08 2022-04-29 沃特世科技公司 用于分析抗体-药物缀合物的多维色谱方法
US11896683B2 (en) 2016-12-16 2024-02-13 The Australian National University Radiolabelled material for targeted administration
DK3568205T3 (da) 2017-01-12 2023-10-09 Radiomedix Inc Behandling af cancerceller, der overeksprimerer somatostatinreceptorer ved at anvende radioisotop-chelaterede ocreotid-derivater
EP3661557B1 (en) * 2017-07-31 2025-09-03 Actinium Pharmaceuticals, Inc. Treatments for a hematological malignancy
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
WO2022056354A1 (en) * 2020-09-11 2022-03-17 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
US12551584B1 (en) 2020-12-07 2026-02-17 Actinium Pharmaceuticals, Inc. Lewis Y radioimmunotherapy for the treatment of cancer
US12447218B1 (en) * 2021-02-09 2025-10-21 Actinium Pharmaceuticals, Inc. Radioconjugates directed to MHC-complexed antigens in cancer
US20250339571A1 (en) * 2021-08-27 2025-11-06 Actinium Pharmaceuticals, Inc. Radioimmunoconjugates targeting phosphatidylserine for use in the treatment of cancer
WO2023183927A2 (en) 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
US20250177583A1 (en) 2022-03-30 2025-06-05 Nihon Medi-Physics Co., Ltd. Method for producing complex
EP4536278A2 (en) 2022-06-07 2025-04-16 Actinium Pharmaceuticals, Inc. Bifunctional chelators and conjugates
US20250388688A1 (en) 2024-04-04 2025-12-25 Ethyreal Bio, Inc. Anti-tshr antibodies and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001387A (en) 1973-07-30 1977-01-04 Medi-Physics, Inc. Process for preparing radiopharmaceuticals
US4305922A (en) 1978-10-04 1981-12-15 University Patents, Inc. Labeling proteins with 99m-Tc by ligand exchange
US4296785A (en) 1979-07-09 1981-10-27 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US4454106A (en) 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4732864A (en) 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4894364A (en) 1983-10-26 1990-01-16 Greer Sheldon B Method and materials for sensitizing neoplastic tissue to radiation
US4828991A (en) 1984-01-31 1989-05-09 Akzo N.V. Tumor specific monoclonal antibodies
US4663129A (en) 1985-01-30 1987-05-05 The United States Of America As Represented By The United States Department Of Energy Isotopic generator for bismuth-212 and lead-212 from radium
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5306509A (en) 1987-03-17 1994-04-26 Turner Robert E Prevention and treatment of oral lesions
AU2068588A (en) 1987-08-12 1989-02-16 Immunomedics Inc. Preparation of radiolabeled conjugates
US4833329A (en) 1987-11-20 1989-05-23 Mallinckrodt, Inc. System for generating and containerizing radioisotopes
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
AU630362B2 (en) 1988-05-25 1992-10-29 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Macrocyclic chelates & methods of use thereof
US4923985A (en) 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
US5292868A (en) 1989-05-26 1994-03-08 Akzo N.V. Chelating agents for attaching metal ions to proteins
DE69007430T2 (de) 1989-06-19 1994-07-07 Akzo Nobel N.V., Arnheim/Arnhem Radioimmuntherapie unter alphapartikelausstrahlung.
CA2063551C (en) 1989-07-12 2000-05-16 Jacobus D.M. Herscheid Method for preparing radiodiagnostic gaseous radionuclide and apparatus
US5443816A (en) 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
LU87684A1 (de) 1990-02-23 1991-10-08 Euratom Verfahren zur erzeugung von aktinium-225 und wismut-213
US5038046A (en) 1990-07-10 1991-08-06 Biotechnetics Method and generator for producing radioactive lead-212
US6403771B1 (en) 1991-02-19 2002-06-11 Actinium Pharmaceuticals, Limited Method and means for site directed therapy
CA2100709C (en) 1992-07-27 2004-03-16 Maurits W. Geerlings Method and means for site directed therapy
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US6458933B1 (en) 1998-05-20 2002-10-01 Immunomedics, Inc. Therapeutic using a bispecific antibody
ES2299256T3 (es) 1998-05-26 2008-05-16 Sloan-Kettering Institute For Cancer Research Constructos que emiten particulas alfa y sus usos.
WO1999066951A2 (en) 1998-06-22 1999-12-29 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
AU2002211232B2 (en) 2000-09-15 2006-10-19 Sloan Kettering Institute For Cancer Research Targeted alpha particle therapy using actinium-225 conjugates
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US20040136908A1 (en) 2001-04-09 2004-07-15 Olson William C. Anti-cd19 immunotoxins
US7666414B2 (en) 2001-06-01 2010-02-23 Cornell Research Foundation, Inc. Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
AU2003210149B2 (en) 2002-01-03 2008-10-09 Bayer Schering Pharma Aktiengesellschaft Conjugates comprising an antibody specific for the ED-B domain of fibronectin and their use for the detection and treatment of tumours
US20040022726A1 (en) 2002-06-03 2004-02-05 Goldenberg David M. Methods and compositions for intravesical therapy of bladder cancer
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US20060058218A1 (en) 2004-09-10 2006-03-16 General Electric Company Solid phase conjugation of complexing agents and targeting moieties
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
EP2015775B1 (en) 2006-05-03 2011-06-01 Bayer Schering Pharma Aktiengesellschaft Combination of an anti edb fibronectin domain antibody l19-sip and an anti-egfr antibody

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12344675B2 (en) 2022-08-22 2025-07-01 Abdera Therapeutics Inc. Polypeptide comprising a single-domain antibody variable region that binds delta-like ligand 3 (DLL3) and method of use thereof to make a radionuclide complex
US12600794B2 (en) 2024-07-23 2026-04-14 Abdera Therapeutics Inc. 5T4 binding polypeptides and uses thereof

Also Published As

Publication number Publication date
CA2768658A1 (en) 2011-01-27
CN102596258B (zh) 2015-01-28
CN104710504B (zh) 2019-09-13
RU2704802C2 (ru) 2019-10-31
RU2015137512A (ru) 2018-12-25
JP2016199583A (ja) 2016-12-01
EP2456472A4 (en) 2014-08-27
RU2565402C2 (ru) 2015-10-20
RU2012106301A (ru) 2013-08-27
HK1211304A1 (en) 2016-05-20
EP2456472A1 (en) 2012-05-30
RU2015137512A3 (https=) 2019-04-02
EP2456472C0 (en) 2024-03-27
CA2768658C (en) 2018-04-03
IN2012DN00551A (https=) 2015-06-12
WO2011011592A1 (en) 2011-01-27
JP2013500258A (ja) 2013-01-07
CN104710504A (zh) 2015-06-17
US20120220754A1 (en) 2012-08-30
EP2456472B1 (en) 2024-03-27
US9603954B2 (en) 2017-03-28
CN102596258A (zh) 2012-07-18

Similar Documents

Publication Publication Date Title
JP5985392B2 (ja) 放射性免疫複合体を生成するための方法
JP2025143317A (ja) ポリペプチドの放射性標識
Sarrett et al. Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy
Di Bartolo et al. New 64 Cu PET imaging agents for personalised medicine and drug development using the hexa-aza cage, SarAr
EP1933883B1 (en) Methods and compositions for diagnosis of iga-and igm-mediated kidney diseases
Sakahara et al. Avidin–biotin system for delivery of diagnostic agents
CA2489469C (en) Monoclonal antibody pam4 and its use for diagnosis and therapy of pancreatic cancer
Karacay et al. Experimental pretargeting studies of cancer with a humanized anti-CEA× murine anti-[In-DTPA] bispecific antibody construct and a 99mTc-/188Re-labeled peptide
ES3057687T3 (en) Dota-hapten compositions for anti-dota/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy
Vugts et al. Synthesis of phosphine and antibody–azide probes for in vivo Staudinger ligation in a pretargeted imaging and therapy approach
AU2010200271A1 (en) Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B
KR20240035757A (ko) 우로키나제 플라스미노겐 활성화제 수용체-표적화된 방사성 약제
Karacay et al. Pretargeting for cancer radioimmunotherapy with bispecific antibodies: role of the bispecific antibody's valency for the tumor target antigen
Coliva et al. 90Y Labeling of monoclonal antibody MOv18 and preclinical validation for radioimmunotherapy of human ovarian carcinomas
JP2023527385A (ja) 抗ｇｄ２ ｓａｄａコンジュゲート及びその使用
Chen et al. Site-specific Conjugation of 6 DOTA Chelators to a CA19-9-targeting scFv-Fc Antibody for Imaging and Therapy
Yoo et al. N-acetylgalactosamino dendrons as clearing agents to enhance liver targeting of model antibody-fusion protein
CN119874942B (zh) 一种放射性蛋白偶联药物及其应用
US20150157742A1 (en) SYNTHESIS OF BIOLOGICAL COMPOUNDS LABELED WITH THE ALPHA EMITTER Ac-225
N’Guessan et al. Enhancing theranostic potential of anti-mesothelin sdAb through site-specific labeling at a unique conserved lysine by molecular engineering
Bejot et al. Aminooxy‐functionalized DOTA for radiolabeling of oxidized antibodies: evaluation of site‐specific 111In‐labeled trastuzumab
HK1211304B (zh) 用於制备放射性免疫缀合物的方法
CA2836313A1 (en) Synthesis of biological compounds labeled with the alpha emitter ac-225
Bensimon et al. Antibody radiolabeling
EA045797B1 (ru) Радиоактивное мечение полипептидов

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151007

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160407

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160803

R150 Certificate of patent or registration of utility model

Ref document number: 5985392

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250